Joint clinical assessment, shifting HTA demands and pricing pressure are making launch the start of continuous evidence generation.
Chris Cameron
Advertisement
Chris Cameron, Ph.D., is chief scientific officer, global value & evidence with EVERSANA, and a global thought leader in HEOR and HTA.
Articles by Chris Cameron
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
When Drug Pricing Collides With Politics
2
China-Sourced KSMs Leave Vital 40 Exposed, APIIC Warns
3
How CMS’ Final Negotiation Rule Treats New Drug Formulations
4
The AI Efficiency Trap: Why Faster Tasks Alone Won’t Transform Life Sciences
5